S-304 CTEPH DB study
Phase 2
- Conditions
- Chronic thromboembolic pulmonary hypertension (CTEPH)
- Registration Number
- JPRN-jRCT2080221626
- Lead Sponsor
- IPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
CTEPH patient as demonstrated the deficit of lung perfusion by ventilation/perfusion lung scanning and pulmonary angiography
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method